Literature DB >> 2669685

Vaccinia virus: a suitable vehicle for recombinant vaccines?

C Kaplan1.   

Abstract

The complications of vaccination against small pox are discussed in relation to the contemplated use as vaccines of recombinant vaccinia viruses carrying the genes for "protective" antigens derived from a range of pathogens. Recombinant vaccines are potentially extremely valuable instruments in the fight against infectious diseases, but caution is needed in their deployment. In addition to the dangers associated with the pathogenicity of various strains of vaccinia virus, there may be problems related to the ecology of the poxviruses--especially orthopoxviruses. Before recombinant vaccinia virus vaccines are widely used, ecological research is urgently needed. It should cover not only the ecology of orthopoxviruses, but also possible interactions between engineered vaccinia viruses released into the environment and wild viruses which may be resident in both target and non-target species in a wide selection of habitats.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2669685     DOI： 10.1007/bf01311044

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  44 in total

1.  ILLNESSES ATTRIBUTED TO SMALLPOX VACCINATION, 1951-60. II. ILLNESSES REPORTED AS AFFECTING THE CENTRAL NERVOUS SYSTEM.

Authors:  E T CONYBEARE
Journal:  Mon Bull Minist Health Public Health Lab Serv       Date:  1964-09

2.  THE USE OF CEILING TEMPERATURE AND REACTIVATION IN THE ISOLATION OF POX VIRUS HYBRIDS.

Authors:  K R DUMBELL; H S BEDSON
Journal:  J Hyg (Lond)       Date:  1964-06

3.  [On the variation in "incubation time" of postvaccinal cerebral disease].

Authors:  G WEBER; J LANGE
Journal:  Dtsch Med Wochenschr       Date:  1961-08-04       Impact factor: 0.628

4.  Titration of vaccinia virus by intravenous injection of chick embryos.

Authors:  C KAPLAN
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

5.  Evidence for the existence of latent myxoma virus in rabbits (Oryctolaqus cuniculus(L.)).

Authors:  R T Williams; J D Dunsmore; I Parer
Journal:  Nature       Date:  1972-07-14       Impact factor: 49.962

6.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

7.  A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo.

Authors:  I D Ladnyj; P Ziegler; E Kima
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

8.  Isolation of poxvirus from an African Rodent.

Authors:  B Lourie; J H Nakano; G E Kemp; H W Setzer
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226

9.  A COMPARATIVE STUDY OF CLINICAL REACTION OBSERVED AFTER APPLICATION OF SEVERAL SMALLPOX VACCINES IN PRIMARY VACCINATION OF YOUNG ADULTS.

Authors:  M F POLAK; B J BEUNDERS; A R VAN DER WERFF; E W SANDERS; J VAN KLAVEREN; L M BRANS
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

10.  CULTIVATION OF VACCINE VIRUS FOR JENNERIAN PROPHYLAXIS IN MAN.

Authors:  T M Rivers
Journal:  J Exp Med       Date:  1931-09-30       Impact factor: 14.307
View more
  11 in total

1.  Post-vaccination dermatolipomyonecrosis.

Authors:  Dinko Bagatin; Goran Augustin; Tomica Bagatin
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model.

Authors:  T A Brandt; B L Jacobs
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  The amino terminus of the vaccinia virus E3 protein is necessary to inhibit the interferon response.

Authors:  Stacy D White; Bertram L Jacobs
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

Review 4.  Replicating poxviruses for human cancer therapy.

Authors:  Manbok Kim
Journal:  J Microbiol       Date:  2015-04-08       Impact factor: 2.902

5.  Serological evidence for the reservoir hosts of cowpox virus in British wildlife.

Authors:  A C Crouch; D Baxby; C M McCracken; R M Gaskell; M Bennett
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

6.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination.

Authors:  Sangeetha Vijaysri; Garilyn Jentarra; Michael C Heck; Andrew A Mercer; Colin J McInnes; Bertram L Jacobs
Journal:  Vaccine       Date:  2007-12-04       Impact factor: 3.641

7.  Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity.

Authors:  T Rümenapf; R Stark; G Meyers; H J Thiel
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

8.  The infectious bursal disease virus RNA-binding VP3 polypeptide inhibits PKR-mediated apoptosis.

Authors:  Idoia Busnadiego; Ana M Maestre; Dolores Rodríguez; José F Rodríguez
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

9.  Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses.

Authors:  Susan A Holechek; Karen L Denzler; Michael C Heck; Jill Schriewer; R Mark Buller; Fatema A Legrand; Paulo H Verardi; Leslie A Jones; Tilahun Yilma; Bertram L Jacobs
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

10.  Lineage specific antigenic differences in porcine torovirus hemagglutinin-esterase (PToV-HE) protein.

Authors:  Jaime Pignatelli; Julio Alonso-Padilla; Dolores Rodríguez
Journal:  Vet Res       Date:  2013-12-23       Impact factor: 3.683
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.